Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + cladribine with rituximab maintenance in chronic lymphocytic leukemia and small lymphocytic lymphoma
2010-018519-14Phase 2Terminated
- Sponsor
- European Institute of Oncology
- Start
- Nov 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab and cladribine in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by European Institute of Oncology. Primary endpoints: Duration of response and Time to progression. Started Nov 2010; status: terminated.
02
Drugs
rituximabcladribine
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2010-018519-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018519-14.